Clinical Trial Update: Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating surufatinib in combination with envolizumab as second-line treatment for recurrent/metastatic head and neck cancer is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Envolizumab (envolizumab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Head and Neck Cancer, Head and Neck Cancer Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING